Purchase this article with an account.
E.S. Arcieri, A.C. A. Pereira, E.G. V. Andreo, I.G. A. Finotti, R.S. Arcieri, W.F. Sá Filho; Fixed Combination Brimonidine–Timolol (Combigan®) versus Fixed Combination Dorzolamide–Timolol (Cosopt®) Each Given Twice Daily to Reduce Intraocular Pressure in Subjects With Open Angle Glaucoma or Ocular Hypertension . Invest. Ophthalmol. Vis. Sci. 2006;47(13):434.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy of fixed combination brimonidine–timolol (Combigan®) versus fixed combination dorzolamide–timolol (Cosopt®) given twice daily in primary open angle glaucoma or ocular hypertension subjects.
In this prospective, multicenter, masked–observer, crossover comparison 30 subjects were washed out from their previous medication and randomized to Combigan® or Cosopt® for the first 4–week treatment period. Subjects then were washed for 4 weeks and started on the opposite medication for the second 4–week period. Intraocular pressure (IOP) was measured at 8:00 am, 12:00 pm, and 4:00 pm at each baseline and at the end of each treatment period. Unsolicited ocular adverse events were also recorded.
The baseline mean diurnal IOP for all 30 subjects (30 eyes) was 22.9 ± 1.6 mmHg. Both fixed combinations significantly reduced IOP compared with baseline (p<0.00001). The mean diurnal IOP following 4 weeks of therapy was 15.0 ± 2.1 mmHg for Combigan® and 15.4 ± 2.1 mmHg for Cosopt® (p=0.5097). The mean percentage reduction in diurnal IOP was 34.3 ± 8.5% for Combigan® and 32.9 ± 8.6% for Cosopt® (p=0.5456). Overall, 14 subjects complained about ocular adverse events: 2 only for Combigan®, 7 only for Cosopt® and 5 for both drugs. Although there was no significant difference between the number of subjects that reported ocular adverse events with Combigan® (n=7) and Cosopt® (n=12) (p=0.2669), Cosopt® caused more ocular stinging upon instillation (n=9) than Combigan® (n=1) (p=0.0198).
This study suggests that Combigan® and Cosopt®, each given twice daily, have similar efficacy in primary open angle glaucoma or ocular hypertensive subjects.
This PDF is available to Subscribers Only